Contact
searchSearch
HMP Global
Login

Tardive Dyskinesia - High Opp Excellence Forum

Tardive Dyskinesia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Brooke Kempf, PMHNP-BC, and Jonathan Meyer, MD
Q&A
Recognizing Key Differences Between TD and Drug-Induced Parkinsonism
03/10/2026
Brooke Kempf, MSN, PMHNP-BC; Jonathan Meyer, MD
In this Q&A, Brooke Kempf, PMHNP-BC, Steering Committee, Psych Congress, and Jonathan Meyer, MD, Consultant, Psych Congress, outline the hallmark characteristics of DIP and TD.
In this Q&A, Brooke Kempf, PMHNP-BC, Steering Committee, Psych Congress, and Jonathan Meyer, MD, Consultant, Psych Congress, outline the hallmark characteristics of DIP and TD.
In this Q&A, Brooke Kempf,...
03/10/2026
Psych Congress Network
Brooke Kempf, PMHNP-BC, and Jonathan Meyer, MD
Q&A
Avoiding Anticholinergics in TD and Deprescribing Approaches
02/06/2026
Brooke Kempf, MSN, PMHNP-BC; Jonathan Meyer, MD
In this discussion, Brooke Kempf, PMHNP-BC, and Jonathan Meyer, MD, unpack why anticholinergics are ineffective—and potentially harmful—in patients with tardive dyskinesia (TD). 
In this discussion, Brooke Kempf, PMHNP-BC, and Jonathan Meyer, MD, unpack why anticholinergics are ineffective—and potentially harmful—in patients with tardive dyskinesia (TD). 
In this discussion, Brooke...
02/06/2026
Psych Congress Network
Greg Mattingly, MD
Videos
VMAT-2 Inhibitor Differences and Dosing in Tardive Dyskinesia
01/09/2026
Greg Mattingly, MD
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg...
01/09/2026
Psych Congress Network
Greg Mattingly, MD
Videos
Distinguishing Tardive Dyskinesia From Other Movement Disorders
09/04/2025
Greg Mattingly, MD
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the...
09/04/2025
Psych Congress Network
Desiree Matthews
Videos
Anticipating Medication Interactions in Tardive Dyskinesia
08/01/2025
Desiree Matthews, PHMNP-BC
Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, walks clinicians through common medication interactions to be aware of as they develop treatment plans for patients with TD.
Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, walks clinicians through common medication interactions to be aware of as they develop treatment plans for patients with TD.
Desiree Matthews, PMHNP-BC,...
08/01/2025
Psych Congress Network
Jonathan Meyer Promo
Quiz
Tailoring Patient-Centered Treatment Approaches for TD
06/27/2025
Jonathan Meyer, MD
Do you remember Dr Meyer's recommendations?
Do you remember Dr Meyer's recommendations?
Do you remember Dr Meyer's...
06/27/2025
Psych Congress Network
Kristian Dambrino
Videos
Navigating Complexities in the Management of Tardive Dyskinesia
06/05/2025
Kristian Dambrino, MSN, APRN, PMHNP
In this video filmed at Psych Congress 2024, Kristian Dambrino, DNP, PMHNP-BC, shares practical insights on tackling challenges that may arise when treating patients with tardive dyskinesia (TD).
In this video filmed at Psych Congress 2024, Kristian Dambrino, DNP, PMHNP-BC, shares practical insights on tackling challenges that may arise when treating patients with tardive dyskinesia (TD).
In this video filmed at Psych...
06/05/2025
Psych Congress Network
Jonathan Meyer PCN Headshot
Videos
Keeping Patient Needs at the Center of Tardive Dyskinesia Treatment
04/30/2025
Jonathan Meyer, MD
In this video, Psych Congress Steering Committee Member Jonathan Meyer, MD, explores TD treatment approaches that can optimize a patient’s overall well-being.
In this video, Psych Congress Steering Committee Member Jonathan Meyer, MD, explores TD treatment approaches that can optimize a patient’s overall well-being.
In this video, Psych Congress...
04/30/2025
Psych Congress Network
Kristian Dambrino, MSN
Videos
When Monotherapy Doesn’t Work: Treatment Resistance in Tardive Dyskinesia
04/08/2025
Kristian Dambrino, MSN, APRN, PMHNP
Psych Congress Faculty Member Kristian Dambrino, DNP, PMHNP-BC, dives into the nuances of prescribing vesicular monoamine transporter 2 (VMAT-2) inhibitors for the long-term management of TD.
Psych Congress Faculty Member Kristian Dambrino, DNP, PMHNP-BC, dives into the nuances of prescribing vesicular monoamine transporter 2 (VMAT-2) inhibitors for the long-term management of TD.
Psych Congress Faculty Member...
04/08/2025
Psych Congress Network
Desiree Matthews, PMHNP-BC, CEO
Videos
How to Navigate Insurance When Treating Tardive Dyskinesia
01/06/2025
Desiree Matthews, PHMNP-BC
In this video, Desiree Matthews, PMHNP-BC, discusses how to navigate insurance policies when treating tardive dyskinesia.
In this video, Desiree Matthews, PMHNP-BC, discusses how to navigate insurance policies when treating tardive dyskinesia.
In this video, Desiree Matthews,...
01/06/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use